National Health Insurance Service

Curocell's Anbal-cel, a CAR-T therapy, has been selected for expedited approval, coverage evaluation, and drug price negotiation by the Ministry of Health and Welfare. Anbal-cel, targeting relapsed or refractory large B-cell lymphoma, showed a 67.1% complete response rate in phase 2 trials. This selection aims to improve patient access to treatment and streamline the approval process.

A community-based, multicenter, prospective, two-arm, parallel-group, outcome assessor-blinded, pragmatic, randomized encouragement design trial with a 12-month follow-up period, conducted at the Institute for Community Care and Health Equity of Chung-Ang University, following the SPIRIT Statement. Participants are recruited through community screening in five urban areas, selected based on eligibility criteria using the Clinical Frailty Scale, and randomized to either a home-based primary care (HBPC) group or usual care group. The study employs a post-randomization consent design and uses both modified intention-to-treat and complier average causal effect analytic methods to estimate treatment effects, aiming to reduce LTC facility admissions and potentially avoidable hospitalizations.

Korea faces hurdles integrating innovative medical tech due to regulatory and reimbursement issues, as discussed at the K-Healthcare Business Forum. Medical IP's AI-based imaging solutions, like DeepCatch X, aim to replace traditional tests but face adoption challenges. Guardant Health urges regulatory reform for liquid biopsy access, while Ybrain's neuroengineering innovations struggle with market entry and reimbursement.